Personalis Collaborates with Sarepta Therapeutics on Immune Response to Precision Genetic Therapeutics
Shots:
- The two companies collaborated to characterize the immune response to precision genetic therapeutics, utilizing Personalis’ advanced analytics
- The collaboration will combine Sarepta’s expertise in precision genetic medicine and Personalis’ advanced neoepitope prediction to characterize certain types of the immune response, benefitting patients with the rare disease
- The Personalis ImmunoID NeXT Platform is designed to adapt to the complex and evolving understanding of cancer, providing its customers with information on all the ~20,000 human genes, together with the immune system, from a single tissue sample
Click here to read full press release/ article | Ref: PRNewswire | Image: Twitter